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Abstract:  Low  cytotoxicity  and  high  gene  transfection efficiency  are  critical  issues  in 
designing current non-viral gene delivery vectors. The purpose of the present work was to 
synthesize the novel biodegradable poly (lactic acid)-poly(ethylene glycol)-poly(L-lysine) 
(PLA-PEG-PLL)  copolymer, and  explore its applicability and  feasibility  as  a  non-viral 
vector for gene transport. PLA-PEG-PLL was obtained by the ring-opening polymerization of 
Lys(Z)-NCA  onto  amine-terminated  NH2-PEG-PLA,  then  acidolysis  to  remove 
benzyloxycarbonyl. The tri-block copolymer PLA-PEG-PLL combined the characters of 
cationic polymer PLL, PLA and PEG: the self-assembled nanoparticles (NPs) possessed a 
PEG  loop  structure  to  increase  the  stability,  hydrophobic  PLA  segments  as  the  core,  
and  the  primary  ε-amine  groups  of  lysine  in  PLL  to  electrostatically  interact  with  
negatively  charged  phosphate  groups  of  DNA  to  deposit  with  the  PLA  core.  The 
physicochemical properties (morphology, particle size and surface charge) and the biological 
properties (protection from nuclease degradation, plasma stability, in vitro cytotoxicity, and 
in vitro transfection ability in HeLa and HepG2 cells) of the gene-loaded PLA-PEG-PLL 
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nanoparticles  (PLA-PEG-PLL  NPs)  were  evaluated,  respectively.  Agarose  gel 
electrophoresis  assay  confirmed  that  the  PLA-PEG-PLL  NPs  could  condense  DNA 
thoroughly and protect DNA from nuclease degradation. Initial experiments showed that 
PLA-PEG-PLL  NPs/DNA  complexes  exhibited  almost  no  toxicity  and  higher  gene 
expression  (up  to  21.64%  in  HepG2  cells  and  31.63%  in  HeLa  cells)  than  PEI/DNA 
complexes (14.01% and 24.22%). These results revealed that the biodegradable tri-block 
copolymer PLA-PEG-PLL might be a very attractive candidate as a non-viral vector and 
might alleviate the drawbacks of the conventional cationic vectors/DNA complexes for 
gene delivery in vivo.  
Keywords:  PLA-PEG-PLL;  nanoparticles;  non-viral  gene  vector;  gene  transfection;  
tri-block copolymer 
 
1. Introduction 
Gene therapy, i.e., the expression of genetic material with therapeutic activity in cells, holds great 
potation for the treatment of human diseases [1]. A gene delivery system, of either viral or non-viral 
vector,  must  be  used  to  carry  the  foreign  gene  into  the target  cell.  Despite  the  high  transduction 
efficiency of viral vectors which are derived from viruses by the use of recombinant DNA techniques, 
their clinical potential should be fully understood in terms of issues related to production, safety and 
immune response that need to be addressed [2]. The safety concerns regarding the use of viral vectors 
in humans make non-viral delivery systems an attractive alternative. The non-viral vectors have recently 
gained increasing attention due to their stability, safety, ease of preparation, and are easily manufactured 
for  large-scale  production  for  treatment  of  numerous  acquired  or  inherited  human  diseases  [3,4]. 
Unfortunately,  non-viral  gene  delivery  vehicles  often  affect  cell  viability  and  have  poor  
transfection efficiency. 
The application of non-viral  gene delivery vectors,  including liposomes,  cationic polymers  and 
polymeric nanoparticles (NPs), could reduce or avoid immunogenicity and associated risks of toxicity. 
The versatility for formulation, sustained release properties, sub-cellular size and biocompatibility with 
tissues and cells make nanoparticles a promising system to achieve ideal gene tranfection [5]. The 
nanoparticles prepared by biocompatible and biodegradable poly (D,L-lactide-co-glycolide) (PLGA) 
and  poly  (D,L-lactide)  (PLA)  polymers  have  attracted  much  attention  because  of  their  favorable 
physicochemical characteristics in terms of safety, stability, the relative ease of large-scale production, and 
lack of intrinsic immunogenicity that make them suitable candidates for gene delivery application [6–8]. 
These  biodegradable  polymers  undergo  hydrolysis  upon  implantation  into  the  body,  forming 
biologically compatible and metabolizable moieties (lactic acid and glycolic acid) that are eventually 
removed from the body by the citric acid cycle [5]. However, an important problem with PLA is 
inadequate  interaction  between  the  polymers  and  cells,  and  these  polymeric  NPs  can  be  easily 
displaced  by  serum  proteins,  which  can  lead  to  aggregation  of  NPs.  Incorporation  of  additional 
excipients  such  as  polyethylene  glycol  (PEG)  has  been  attempted  as  a  method  to  prevent  the 
generation of an extremely acidic microenvironment inside the NPs on polymer degradation [9]. PEG Int. J. Mol. Sci. 2011, 12                       
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has been used to coat the PLA NPs, and could often improve the solubility of the NPs, minimize their 
aggregation, reduce their interaction with proteins in the physiological fluid, and finally, produce a 
shielding  effect  that  counteracts  effective  DNA  complexation  and  steric  stabilization  to  the  gene 
vectors’ surfaces to improve transfection efficiency [10,11]. Because the PLA-PEG block copolymer 
has an amphiphilic character, it forms polymeric micelles in an aqueous milieu, the core is surrounded 
by  a  palisade  of  tethered  PEG  chains  with  an  appreciably  stretched  conformation  [12]  that  have 
predominant  characteristics  such  as  a  long  blood  circulation  time,  biodistribution  and  lower 
interactions with the reticuloendothelial system (RES) [10]. Generally, plasmid DNA is encapsulated 
into  PLA  particles  using  the  common  water-in-oil-water  (W/O/W)  double  emulsion/solvent 
evaporation  method  in  order  to  protect  plasmid  DNA  and  control  the  release  process  [11,13]. 
However,  these  preparation  methods  can  not  guarantee  the  integrity  and  can  even  result  in  the 
degradation of DNA under the ultra-sonication or high speed homogenization which is necessary in the 
encapsulation process to obtain smaller particle sizes [14]. To protect the DNA cargo, one approach in 
the application of PLGA NPs for nucleic acid delivery uses adsorption of the anionic DNA molecules 
onto cationic NPs by the use of cationic surfactants, like cetyltrimethyl ammonium bromide (CTAB), and 
3,2'-dimethyl-4-aminobiphenyl (DMAB) in the formulations [15]. In our previous studies, Zou et al. 
also investigated how gene loaded cationic PLA-PEG NPs modified by CTAB could successfully 
transfect a gene into HeLa cells even in the presence of serum [16]. However, there is no doubt that 
introduction of cationic surfactants would generate cytotoxicity. The polar and hydrophobic domains 
of cationic surfactants may have dramatic effects on both transfection and toxicity levels [17]. 
On the basis of PLA-PEG, as previously, in order to avoid the use of cationic surfactants, here we try to 
design  a  biodegradable  tri-block  copolymer  poly(lactic  acid)-poly(ethylene  glycol)-poly(L-lysine) 
(PLA-PEG-PLL), which combines the characters of cationic polymer PLL, biodegradable polymer 
PLA and PEG, which was selected as the shell-forming segment due to its physicochemical characteristics, 
including high water solubility and significant chain mobility as well as its low toxicity [12]. The cationic 
polymer, poly(L-lysine) (PLL) has been widely applied in gene delivery vectors. The primary ε-amine 
groups of lysine in PLL could electrostatically interact with negatively charged DNA [18] and help to 
improve the affinity to proteins and cells. Based on the electrostatic binding with the tumor cell, PLL-based 
cationic and biodegradable polymeric micelles are expected to permeate tumor cells more feasibly [19]. In 
addition, due to the large number of active functional groups with amino, PLL could be modified with 
various kinds of ligands to achieve active targeting to tissues and cells. 
Compared with various kinds of polymers, cationic polymer PLL was biodegradable but exhibited 
low  transfection  efficiency.  PEI  was  considered  as  one  of  most  efficient  currently-available 
transfection  reagents,  but  this  molecule  is  not  biodegradable  and  relatively  cytotoxic.  Cationic  
PLA-PEG NPs modified with cationic surfactants would induce cytotoxicity, while PLA-PEG-PLL 
NPs  were  biodegradable,  induced  low  cytotoxicity  and  possessed  a  positive  charge  without  any 
cationic  surfactants.  Based  on  these  considerations,  the  main  goal  of  the  present  work  was  to 
synthesize  PLA-PEG-PLL  and  explore  its  applicability  and  feasibility  as  a  non-viral  vector  for  
gene transport. 
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2. Results and Discussion  
The synthetic route of PLA-PEG-PLL is shown in Scheme 1. The method has been described in the 
literature by Lu et al. [20]. 
Scheme 1. Schematic synthetic route of poly(lactic acid)-poly(ethylene glycol)-poly(L-lysine) 
(PLA-PEG-PLL). 
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2.1. Synthesis of PLA-PEG-PLL 
PLA-PEG-PLL  was  analyzed  by 
1H-NMR  using  DMSO-D6  (Figure  1)  as  a  solvent.  PLA:  
(δCH3) = 1.56 ppm, (δ-CH) = 5.15 ppm; PEG: (δ-CH2) = 3.51 ppm; PLL: (δ(CH2)3) = 1.22–1.29,  
(δ-CH2)  =  2.51,  (δ(-HN-CH<))  =  4.18.  The  GPC  of  the  tri-block  copolymer  PLA-PEG-PLL  was 
performed to determine the molecular weight of 17,500 and the polydispersity index (PDI) of 1.17. 
The molecular weight of each polymer, PEG average Mn 2,000, PLA average Mn 13,500 and PLL 
average Mn 2,000, were also measured. 
Figure 1. The
 1H NMR spectra of PLA-PEG-PLL. 
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2.2. Formation and Physicochemical Characterization of Cationic PLA-PEG-PLL NPs and PLA-PEG-PLL 
NPs/DNA Complexes 
In  the  present  study,  based  on  our  previously  research  on  PLA-PEG,  we  have  designed  and 
synthesized PLA-PEG-PLL which self-assembled to form cationic nanoparticles in aqueous solution, 
then adsorbed DNA via self-assembly nanotechnology based on alternative deposition of oppositely 
charged  compounds.  In  this  nanoparticle  system,  hydrophobic  PLA  segments  as  the  core  could 
increase  the  stability  of  the  system;  due  to  the  primary  ε-amine  groups  of  lysine,  PLL  segments 
provide a positive charge which combine with DNA, deposited into the core; the aggregated segments 
are quickly stabilized by hydrophilic PEG chains which form a loop structure around the nanoparticles. 
The loop structure might increase the thickness of the PEG adsorption layer. The more loops at the 
interface,  the  thicker  the  adsorption  layer  [21].  PEGylation  further  increased  the  stability  of  the 
nanoparticles  and  reduced  their  interaction  with  proteins  in  the  physiological  fluid  greatly.  The 
schematic illustration of the preparation of NPs/DNA complexes is shown in Figure 2. This structure 
concord with self-assembled micelles based on PLL-PEG-PLL copolymers was described by Zhuo [22]. 
Figure 2. Schematic illustration of PLA-PEG-PLL NPs/DNA complexes. 
 
The formulations of PLA-PEG-PLL NPs and PLA-PEG-PLL NPs/DNA complexes were evaluated 
by the particle size, polydispersity index and zeta potential. Transmission electron micrographs of the 
PLA-PEG-PLL NPs and NPs/DNA complexes are shown in Figure 3. It is shown that the obtained 
NPs exhibited a similar uniform spherical shape with a smooth surface and were separated from each 
other. When the N/P ratio is 15 or higher, the diameters of the complexes are all smaller than 150 nm, 
which  is  suitable  for  gene  delivery,  since  it  has  been  reported  that  carrier/DNA  complexes  with 
diameters larger than 150 nm were difficult for many types of mammalian cells to endocytose [23]. 
When the NPs/DNA ratio is 12 or lower, the diameters of complexes are relatively bigger (~230 nm), 
indicating that the NPs/DNA complexes may be loose and the DNA in the complex is not thoroughly 
condensed. Mean particle sizes of PLA-PEG-PLL NPs and NPs/DNA complexes (N/P ratios 15:1) 
were 78.8 ±  4.5 nm and 127.4 ±  6.7 nm respectively. The polydispersity index (PDI) of two kinds of 
nanoparticles ranged from 0.14 to 0.18, which demonstrated a relatively narrow particle size range. 
Zeta potential  is  another important  index for the stability of the NPs  suspension. Analysis  of the 
surface charge of the NP complexes showed that when the N/P ratio was increased from 9 to 15, the Int. J. Mol. Sci. 2011, 12                       
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complexes that were initially negatively charged at approximately −10.3 mV became positively charged at 
+14.9 mV. Increases in the N/P ratio (up to 21) did not further modify the zeta potential value (+25 mV). A 
positive zeta potential of NPs/DNA complexes is necessary to ensure the uptake of nanoparticles by 
cells because a positive surface charge allows an electrostatic interaction between negatively charged 
cellular membranes and the positively charged complexes [24]. 
Figure  3.  Transmission  electron  micrographs  (TEM)  of  PLA-PEG-PLL  NPs  (A)  and  
PLA-PEG-PLL NPs/DNA complexes (B). 
 
Our group previously demonstrated that the cationic surfactant CTAB modified PLA-PEG formed 
cationic nanoparticles, which could adsorb DNA on the surface and successfully transfer plasmid DNA 
into HeLa cells [16]. The cationic surfactant CTAB was shown to be effective for absorbing DNA onto 
the  surface  nanoparticles.  The  addition  of  CTAB  could  increase  the  zeta  potential  of  the  NPs  in 
comparison to the anionic zeta potential of the non-modified NPs [17]. However, a concern with 
coating  the  surface  of  particles  with  cationic  polymers  is  cellular  toxicity.  At  high  coating 
concentrations of CTAB, membrane toxicity was observed in cells [25]. Similarly, PLL has been able 
to change the surface charge when used as an emulsifier in the fabrication of nanoparticles [26]. The 
use of cationic polymers to condense DNA for transfection of cancer cells has been well studied. 
Recently,  this  interaction  has  been  explored  to  enhance  the  gene  transfection  of  biodegradable 
nanoparticles. Blum et al. conjugated PLL to PLGA to create an electrostatically favorable interaction 
between the carrier material and the DNA, and the particles were shown to successfully transfect COS 
cells  [27].  Capan  et  al.  have  encapsulated  DNA  previously  complexed  with  PLL  into  PLGA 
microparticles and demonstrated the ability to control release of these complexes by using different 
molecular weight polymers or changing the surfactant concentration [28]. 
2.3. Gel Retardation Assay 
Generally, cationic nanoparticles could efficiently adsorb anionic plasmid DNA on the surface, to 
form  NPs/DNA  complexes,  primarily  via  electrostatic  attraction.  Agarose  gel  electrophoresis  was 
carried out to confirm whether the plasmid DNA could be associated with the cationic PLA-PEG-PLL 
NPs, and to qualitatively investigate the optimal N/P ratio of NPs to DNA (defined as the molar ratio Int. J. Mol. Sci. 2011, 12                       
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of amino groups in the PLL to phosphate groups in the DNA) for the binding efficiency. Different 
complexes were prepared at N/P ratios of 9:1, 12:1, 15:1, 18:1, 21:1 and 24:1 by using PLA-PEG-PLL 
NPs  to  DNA  and  the  retardation  in  the  migration  of  the  plasmid  DNA  during  agarose  gel 
electrophoresis was examined. As shown in Figure 4, it was observed that naked plasmid DNA (lane 1) 
could migrate to the positive electrode under the electric field, leading to visualization of two bands 
corresponding to open circular and supercoiled morphology. Once DNA was associated with the NPs 
to form complexes, the mobility of DNA was hindered and it was detained in the well of the agarose 
gel. The part of DNA that did not bind the NPs migrated to the positive electrode in the same manner 
asa the control DNA. When the N/P ratio of PLA-PEG-PLL NPs to DNA reached 15:1 or above, 
almost all DNA was combined with NPs without free DNA bands visible in the lane (lane 4–7). Thus, 
NPs/DNA complexes prepared with a ratio of 15:1 were selected as the optimal N/P ratio of NPs to 
DNA for further study.  
Figure  4.  Gel  retardation  assay  of  PLA-PEG-PLL  NPs/DNA  complexes  prepared  at 
different N/P ratios. Lane 1: Naked DNA; Lane 2-7: The N/P ratios of PLA-PEG-PLL 
NPs/DNA complexes was 9:1, 12:1, 15:1, 18:1, 21:1 and 24:1, respectively. 
 
2.4. Heparin Replacement 
Another essential consideration was the integrity of the DNA that had been incorporated into the 
NPs. The release of the plasmid DNA from the optimal N/P ratios 15:1 of PLA-PEG-PLL NPs/DNA 
complexes by heparin displacement with different concentration was investigated. As illustrated in 
Figure 5, the DNA structure still remained a complete structure corresponding to open circular and 
supercoiled morphology when it was extracted by heparin of final concentration 1% and 2% (lane 2 and 
lane 3), while with increased heparin concentration the DNA structure was degraded, especially at a 
final concentration of 10%, where the open circular and supercoiled morphology was not observed 
completely.  Thus,  heparin  at  a  final  concentration  of  1%  was  selected  as  the  optimal  extraction 
condition for further study. 
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Figure  5. Plasmid DNA extracted from the PLA-PEG-PLL NPs/DNA complexes (N/P 
15:1) by the addition of different concentration of heparin solution. Lane 1: Naked DNA; 
Lane2-5: PLA-PEG-PLL NPs/DNA complexes extracted with 1% heparin, 2% heparin, 
5% heparin and 10% heparin, respectively. 
 
2.5. Stability of PLA-PEG-PLL NPs/DNA Complexes in Plasma 
Agarose gel electrophoresis was carried out to investigate whether the PLA-PEG-PLL NPs/DNA 
complexes could be stable in human plasma. Figure 6 showed the stability with the N/P ratio 15:1 of 
NPs/DNA complexes in plasma. It could be observed that the plasmid DNA  alone was degraded 
completely  by  nucleases  in  plasma  with  the  exposure  of  10%  human  plasma  for  1  h  in  lane  2. 
However, in the presence  of human  plasma,  NPs/DNA complexes  remained  relatively stable, and 
DNA still remained a complete structure corresponding to open circular and supercoiled morphology. 
This result confirmed that the PLA-PEG-PLL NPs could not only adsorb DNA efficiently onto their 
surfaces but could also partially protect the condensed DNA against degradation by plasma proteins. 
This was attributed to PEG modification, which could act to reduce the nanoparticles’ interaction with 
proteins  in  the  physiological  fluid  and  produce  a  shielding  effect  that  counteracts  effective  DNA 
complexation [29].  
Figure  6. Stability of PLA-PEG-PLL NPs/DNA complexes (N/P 15:1) in 10% human 
plasma. Lane 1: Naked DNA; Lane 2: Naked DNA incubated with human plasma for 2 h; 
Lane 3: NPs/DNA complex  incubated with human plasma for 2 h; Lane 4: NPs/DNA 
complex extracted with 1% heparin. 
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2.6. DNase I Protection Assays 
Effective condensation is a key issue for DNA stability against degradation by nucleases [30]. 
Deoxyribonuclease I (DNase I) or DNase I-like enzymes exist in the extracellular space [31] and 
cellular cytoplasm [32] and have been implicated to play a role in DNA degradation and disruption. 
The ability of cationic nanoparticles to protect against nuclease attack is paramount in enhancing the 
success  of  gene  expression.  To  investigate  whether  PLA-PEG-PLL  NPs  could  protect  adsorbed 
plasmid  DNA  from  digestion  by  nucleases,  the  complexes  were  exposed  to  DNase  I  at  different 
concentrations. As illustrated in Figure 7, naked plasmid DNA (lane 2) was completely digested by 
DNase I at 0.1 U/μg DNA within 30 min of incubation, confirming the activity of nucleases. However, 
DNA extracted from the N/P ratio 15:1 of NPs/DNA complexes through heparin at final concentration 
of 1%, remained intact in supercoiled form in the investigated concentrations of DNase I within 30 min of 
incubation (lane 3–4), similar to the DNA control in lane 1. Our studies showed that PLA-PEG-PLL 
NPs  could  protect  DNA  against  degradation  by  DNase  I,  which  is  one  of  the  crucial  factors  for 
efficient gene delivery in vitro as well as in vivo. 
Figure 7. Agarose gel electrophoresis of PLA-PEG-PLL NPs/DNA complexes (N/P 15:1) 
after  incubation  with  different  concentrations  of  DNase  I.  Lane  1:  Naked  DNA;  
Lane 2: Naked DNA incubated with DNase I at 0.1 U/μg DNA for 30 min; Lane 3–4: 
NPs/DNA complexes incubated with DNase I at 0.1 and 0.2 U/μg DNA, respectively, for 
30 min. 
 
2.7. Cytotoxicity of PLA-PEG-PLL NPs/DNA Complexes  
Non-viral  gene  delivery  systems  have  certain  drawbacks  in  terms  of  cytotoxic  reactions;  thus 
evaluation  of  the  cytotoxicity  of  the  cationic  nanoparticles  is  essential.  The  cytotoxicity  of  
PLA-PEG-PLL  NPs/DNA  complexes  at  various  concentrations  was  evaluated  by  MTT  assay  in 
HepG2 and HeLa cells, in comparison with PEI. As shown in Figure 8, PLA-PEG-PLL NPs/DNA 
complexes showed almost no toxicity (higher than 80%) in both HepG2 and HeLa cell lines at all the 
tested concentrations and the average cell viabilities of different formulations were all significantly 
higher than PEI/DNA (p < 0.05). According to these results, the PLA-PEG-PLL NPs/DNA complexes 
appear  to  be  a  safe  carrier.  The  low  cytotoxicity  of  NPs  may  be  explained  by  the  fact  that  the 
biodegradable tri-block copolymer PLA-PEG-PLL could electrostatically interact with plasmid DNA 
without any cationic surfactants.  Int. J. Mol. Sci. 2011, 12                       
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Figure 8. Cytotoxicity of various concentrations of PLA-PEG-PLL NPs/DNA complexes 
in HepG2 and HeLa cells. PLA-PEG-PLL NPs/DNA concentrations were from 50 μg/mL 
to 500 μg/mL (n = 3, *P < 0.05 compared with PEI). 
 
2.8. In Vitro Transfection Studies 
Designing a safe and efficient non-viral gene delivery system is essential for a variety of gene 
therapy applications. In the present study, all the transfection studies were performed in the presence 
of serum medium to verify whether the hydrophilic PEG as the loop structure could prevent absorption 
of plasma proteins on the surface of the nanoparticles. Transfection ability of our established vectors 
PLA-PEG-PLL  NPs/DNA  complexes  was  investigated  in  comparison  with  PEI/DNA  complexes. 
From fluorescence images (Figure 9), it was shown that naked DNA and PLL/DNA complexes could 
barely transfect either HepG2 or HeLa cells, whereas, both PLA-PEG-PLL NPs/DNA complexes and 
PEI/DNA, could achieve intracellular gene tranfection. The gene transfection efficiency of the complexes 
was then further quantitively determined by ﬂow cytometry and the data are shown in Figure 10.  
In the preliminary tests, we chose PLL (25 kDa) as positive control. The results show that in the 
study of heparin replacement, no matter how high the concentration of heparin, it did not extract DNA 
from PLL/DNA complexes (data not shown). Furthermore, in in vitro transfection studies, PLL/DNA 
complexes barely transfected in HepG2 cells and HeLa cells, as shown in the fluorescence images, and 
only gene expression efficiency of 3.11% and 5.01%, respectively, was obtained (P < 0.01, compared 
with PLA-PEG-PLL NPs/DNA complexes). This might be explained by the fact that PLL condensed 
DNA too tightly to release DNA from the complexes, leading to the lower transfection efficiency. In the 
present study, PEI (25 kDa) was chosen as positive control. PEI (25 kDa) is considered as one of most 
efficient  currently-available  transfection  reagents,  but  this  molecule  is  not  biodegradable  and  is 
relatively  cytotoxicity.  Compared  with  PEI/DNA  complexes,  the  transfection  efficiency  of  
PLA-PEG-PLL NPs/DNA complexes still exhibited higher gene expression  of up to 21.64 % and 
31.63%  (more  than  PEI/DNA  at  14.01%  and  24.22%)  in  HepG2  and  HeLa  cells,  respectively  
(P < 0.05). 
In the presence of serum, PLA-PEG-PLL NPs/DNA complexes maintained visibly higher gene 
transfection activity than PEI/DNA complexes. This might be explained that PEI/DNA complexes Int. J. Mol. Sci. 2011, 12                       
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tended to adsorb anionic serum protein and form a larger aggregate, which could not get across the cell 
membrane and deliver the DNA to the nucleus. PLA-PEG-PLL NPs/DNA complexes with PEGylation 
could prevent nanoparticle aggregation and prevent the non-specific interactions with serum protein 
especially in the transfection medium, and accordingly improve the transfection efficiency of nanoparticles. 
It  was  also  reported  that  PEGylation  indeed  increased  the  stability  of  the  nanoparticles  and  the 
transfection efficiency was not affected even in the present of serum by Liu et al. [33]. All the results 
demonstrated that the PLA-PEG-PLL NPs/DNA complexes could successfully transfect cancer cells 
and be used as a potential delivery system for DNA in cancer gene therapy.  
Figure 9. Fluorescent images of gene transfection of pEGFP-N1 in HepG2 (top panel) and 
HeLa  cells  (bottom)  with  naked  DNA  (A,E),  PEI/DNA  complexes  (B,F),  PEI/DNA 
complexes (C,G), PLA-PEG-PLL NPs/DNA complexes (D,H) (× 200). 
 
3. Experimental Section 
3.1. Material 
pEGFP-N1 was provided by Zhejiang University (China). PicoGreen dsDNA reagent was obtained 
from  Molecular  Probes  (Invitrogen,  USA).  Agarose  was  purchased  from  BIO-WEST  (Spain). 
Goldview was obtained from Beijing Saibaisheng Biological Engineering Co. (Beijing, China). DNase 
I enzyme was obtained from Beijing Yinfeng Century Scientific Develop Co., Ltd (Beijing, China). 
MTT (3-[4,5-dimehyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide) were purchased from Sigma-
Aldrich (China). PEI (25kDa) was from Sigma-Aldrich (China). HepG2 and HeLa cell lines were 
obtained from American Type Culture Collection (ATCC, USA). All the other chemicals and reagents 
used were of analytical purity grade or higher, obtained commercially. 
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Figure 10. Flow cytometry of HepG2 (top panel) and HeLa cells (bottom) transfected with 
pEGFP-N1  with  naked  DNA,  PLL/DNA,  PEI/DNA  and  PLA-PEG-PLL  NPs/DNA 
complexes.  Gene  expression  was  measured  24  h  post  transfection.  The  reported 
transfection efficiency is the ratio of the number of cells producing fluorescent signal to the 
number  of  total  cells.  (*P  <  0.05  compared  with  PEI/DNA  complexes,  ∆P  <  0.01 
compared with PLL/DNA complexes, n = 3). 
 
3.2. Synthesis of PLA-PEG-PLL 
The tri-block copolymer PLA-PEG-PLL was synthesized by the method described previously by  
Lu  et  al.  [20].  Briefly,  tetrahydrofuran,  potassium  hexamethyldisilazane  and  ethylene  oxide  were 
mixed in ice bath for 3 days, then D,L-LA addedfor 8 h to obtain H2N-PEG-PLA. After acidolysis and 
purification, the H2N-PEG-PLA product (PEG 2000) was vacuum-dried at room temperature. The 
H2N-PEG-PLA was dissolved in DMF under argon atmosphere, then Lys(Z)-NCA added. The reaction 
mixture was stirred for 30 h at room temperature. After evaporation of the solvent, the retentate was Int. J. Mol. Sci. 2011, 12                       
 
1383 
dissolved with CH2Cl2, and precipitated with anhydrous ether and filtered. After being filtered, the 
product was vacuum-dried at room temperature. The product was dissolved  in trifluoroacetic acid 
under argon atmosphere, and stirred for 4 h in an ice bath by adding 50% hydrogen bromide/acetic acid 
solution. Then the solution was added into HAc/MeOH mixture. The resulting copolymer PLA-PEG-PLL 
was obtained after being filtered. 
3.3. Preparation of the Blank PLA-PEG-PLL Nanoparticles  
The  blank  PLA-PEG-PLL  NPs  were  prepared  using  the  method  previously  described  by  Choi  
et al. [34]. Briefly, 3 mL organic polymer solution (60 mg of PLA-PEG-PLL dissolved in DMSO) was 
dropped  at  the  rate  of  15  mL/h  in  20  mL  distilled  water  under  moderate  stirring,  leading  to  the 
immediate polymer precipitation. Subsequently, the solution was put in dialysis bag (molecular weight 
cutoff  3,500  Da,  Sigma)  and  dialyzed  against  deionized  water  for  48  h  to  remove  solvent.  The 
deionized water was exchanged in 5 h intervals for 48 h. The dialyzed solution was filtered with a  
0.45 μm syringe filter. Then the blank PLA-PEG-PLL NPs were collected.  
3.4. Preparation of Gene Loaded PLA-PEG-PLL Nanoparticles  
The  gene  loaded  cationic  PLA-PEG-PLL  NPs  to  form  NPs/DNA  complexes  were  obtained  by 
means  of  electrostatic  attraction  between  the  anionic  plasmid  DNA  and  the  blank  cationic 
nanoparticles. Briefly, the reporter gene encoding enhanced green fluorescence protein (pEGFP-N1) 
was mixed in different proportions with the cationic PLA-PEG-PLL NPs, which was suspended in 
NaCl (150 mM), under gentle vortexing for 20 s and incubated for 30 min at room temperature to 
facilitate  complexation.  The  resultant  PLA-PEG-PL  NPs/DNA  complexes  were  directly  used  for 
further study.  
3.5. Agarose Gel Electrophoresis of NPs/DNA Complexes 
In order to further confirm the adsorption of DNA onto the surface of cationic PLA-PEG-PLL NPs, 
agarose  gel  electrophoresis  was  carried  out.  The  gels  were  prepared  with  0.8%  (w/v)  agarose  in  
20 mL TAE buffer (40 mM Tris, 40 mM Acetic acid, 1 mM EDTA, pH 8.5) containing 2 μL goldview 
as stain. A fixed amount (0.5 μg) of DNA was incubated with various amounts of PLA-PEG-PLL NPs in 
NaCl solution (the N/P ratio of PLA-PEG-PLL and DNA was 9:1, 12:1, 15:1, 18:1, 21:1 and 24:1 
respectively).  The  resultant  PLA-PEG-PLL  NPs/DNA  complexes  and  control  plasmid  DNA  were 
applied to gel electrophoresis at a constant 90 V for 20 min. After the electrophoresis, images were 
obtained  using  UV  transilluminator  and  Multimage 
TM Light  Cabinet  (Alpha  Imagers  EC,  Alpha 
Innotech Corporation) to show the location of DNA. 
3.6. Morphology, Particle Size and Zeta Potential 
The morphology of the PLA-PEG-PLL NPs and PLA-PEG-PLL NPs/DNA complexes at N/P ratio 
15:1 was examined by transmission electronic microscopy (TEM) (JEM-1200EX, Japan). Samples 
were prepared by placing a drop of nanoparticle suspension onto a copper grid and air-dried, following 
negative  staining  with  one  drop  of  2%  aqueous  solution  of  sodium  phosphotungstate  for  contrast Int. J. Mol. Sci. 2011, 12                       
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enhancement.  The  air-dried  samples  were  then  directly  examined  under  the  transmission  
electron microscope.  
The mean particle size and zeta potential of the nanoparticles were analyzed by photon correlation 
spectroscopy  (PCS)  with  a  Zetasizer  3000  (Malvern  Instruments,  Malvern,  England).  All 
measurements were carried out in triplicate. The average particle size was expressed in volume mean 
diameter and the reported value was represented as mean ±  S.D. (n = 3). 
3.7. Integrity Analysis of DNA 
To  investigate  the  integrity  of  DNA  from  the  cationic  PLA-PEG-PLL  NPs,  the  plasmid  DNA  
by  heparin  displacement  was  studied.  In  brief,  PLA-PEG-PLL  NPs/DNA  complexes  were  made  at  
N/P ratios of 15:1 of NPs/DNA, after 30 min of incubation, different final concentration of heparin 
solution (1%, 2%, 5%, 10%) was added and the samples were incubated in shaking water bath (100 rpm) 
for 3 h at 37 °C . The configuration of plasmid DNA in the complexes after heparin extraction was 
analyzed by gel electrophoresis with untreated naked DNA as a reference. The samples were applied to 
a 0.8% (w/v) agarose gel in TAE buffer as described above.  
3.8. Stability Study in Human Plasma 
The stability of the PLA-PEG-PLL NPs/DNA complexes was determined in the presence of 20% 
human plasma at 37 ° C [35]. 10 μL of NPs/DNA complexes (N/P 15:1) was incubated with 10 μL of 
human plasma at 37 °C  for 2 h, and naked DNA incubated with 10 μL of human plasma was used as a 
control. To asses the integrity of DNA loaded in the nanoparticles, it was dissociated from the cationic 
nanoparticles by adding heparin solution at final concentration of 1% (w/v) and the suspension was 
then incubated in a shaking water bath (100 rpm) for 3 h at 37 °C . The configuration of plasmid DNA 
was analyzed by gel electrophoresis and untreated naked DNA was used as a reference.  
3.9. DNase I Protection Study 
To test whether PLA-PEG-PLL NPs/DNA complexes can protect the loaded plasmid DNA from 
nucleases  digestion,  the  results  of  DNase  I  mediated  digestion  was  evaluated  using  agarose  gel 
electrophoresis. Cationic nanoparticles were prepared at N/P ratio of 15:1 of NPs/DNA, incubated with 
different amounts of DNase I (0.1 and 0.2 U/μg DNA) in DNase I /Mg
2+ digestion buffer (50 mM,  
Tris-HCl, pH 7.6, and 10 mM MgCl2). Naked DNA (1 μg) was treated with DNase I at 0.1 U/μg DNA 
as a reference. Then the samples were incubated at 37 ° C for 30 min. 5 μL EDTA solution (0.5 M,  
pH 8.0) was added to inactivate the DNase I. The integrity of DNA loaded in the nanoparticles was 
studied by adding heparin solution at a final concentration of 1% (w/v) [36]. Then the PLA-PEG-PLL 
NPs/DNA complexes containing heparin were placed in a 37 °C  shaking water bath at 100 rpm for 3 h. 
After that, the suspension was analyzed by gel electrophoresis as described above. Untreated naked 
DNA was applied to the gel as a control. 
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3.10. In Vitro Cell Viability 
Cytotoxicity of PLA-PEG-PLL NPs/DNA complexes was assayed by MTT assay in HepG2 and 
HeLa cell lines [37]. The cells were seeded into a 96-well microtiter plates at a density of 8 ×  10
3 cells 
per well in 0.2 mL of RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and antibiotics in 
5% CO2 incubator at 37 °C . After 24 h, the culture medium was replaced by 200 μL fresh serum-free 
RPMI 1640 medium with different concentrations of the nanoparticles (expressed as PLA-PEG-PLL 
concentration, 50, 100, 300, 500 μg/mL) and PEI (25 kDa) in comparison. The PEI/DNA complexes 
were formed at a molar ratio of PEI nitrogen to DNA phosphate (N/P ratios) of 10:1 [38]. The applied 
dosage  of  PEI/DNA  complexes  was  proportional  to  that  used  in  transfection  experiments.  After 
incubating for 24 h, the effect of different treatments on cell viability was assessed by the MTT assay. 
Typically,  5  mg/mL  of  MTT  in  PBS  were  added  to  each  well  reaching  a  final  concentration  of  
0.5 mg/mL MTT and incubated for 4 h. Then the supernatants were removed and the formazan crystals 
were dissolved in 100 μL DMSO. Aliquots were drawn from each well and the absorbance at 570 nm 
was determined by a microplate reader (Model 680, BIO-RAD, USA). Cells without addition of MTT 
were used as blank to calibrate the spectrophotometer to zero absorbance. The relative cell viability (%) 
compared  to  control  cells  were  calculated  by  (Asample/Acontrol)  ×   100.  All  treatments  were  done  in 
quadruplicates and all experiments were repeated in triplicates. A paired t-test with P < 0.05 was used 
to establish statistically significant differences between treatments. 
3.11. In Vitro Transfection Efficiency 
The transfection activity of PLA-PEG-PLL NPs/DNA complexes  was  evaluated in  HepG2 and 
HeLa cell lines. The cells were seeded into 12-well plates at a density of about 3 ×  10
5 cells per well in 
1 mL of RPMI 1640 culture medium with 10% FBS, 24 h prior to transfection. At a confluence level of 
70–80%, cells were washed twice with PBS, and, respectively, incubated with 500 μL of media (with 
or without 10% FBS) containing 1 μg DNA in transfection vectors at 37 °C , PLL/DNA complexes and 
PEI/DNA complexes were used as positive control, 1 μg naked DNA was used as negative control. 
The cells were incubated with the vectors for 4 h, in the presence of serum medium. The transfection 
media was then replaced with 1 mL of fresh complete culture media, and the cells were incubated 
sequentially until 24 h post transfection. Detection of expression of pEGFP-N1 was carried out using an 
inverted  fluorescent  microscope  with  an  attachment  for  fluorescent  observation  (OLYMPUS,  ZX71, 
Japan) and the picture was captured using a 4009 objective. After that, all cells were harvested for 
trypsinization and washed in PBS for three times and cell-associated fluorescence was determined by a 
FACSCalibur flow cytometer (BD Biosciences) for quantitative study. For each sample, 10,000 events 
were  collected  and  fluorescence  was  detected.  Signals  were  amplified  in  logarithmic  mode  for 
fluorescence  to  determine  the  positive  events  by  a  standard  gating  technique.  The  percentage  of 
positive events was calculated as the events within the gate divided by the total number of events, 
excluding cell debris. Transfection experiments were performed in triplicate [39]. 
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4. Conclusions 
Development of safe and efficient non-viral vectors receives tremendous attention in the hope to 
find  a  substitute  for  viral  vectors.  The  biodegradable  tri-block  copolymer  PLA-PEG-PLL  was 
synthesized by the ring-opening polymerization of Lys(Z)-NCA onto amine-terminated NH2-PEG-PLA, 
then  acidolysis  to  remove  benzyloxycarbonyl.  The  novel  cationic  PLA-PEG-PLL  NPs/DNA 
complexes could successfully transfer pEGFP-N1 into HepG2 and HeLa cells, and produced higher 
transfection efficiency than PEI, while showing lower cytotoxicity than PEI. The results of this study 
suggest that the tri-block copolymer PLA-PEG-PLL in this work could offer a novel promising non-viral 
nano-device  for  gene  therapy.  Our  future  study  will  focus  on  the  surface-modification  of  the 
biodegradable tri-block copolymer PLA-PEG-PLL with various kinds of ligands to achieve active 
targeting to tissues and cells to build the “perfect vector” for systemic gene therapy against cancer. 
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